2003

Treatment issues for women

1 March 2003. Related: On the web.

Depression and HIV

1 March 2003. Related: On the web.

Resistance algorithms updated

1 March 2003. Related: On the web.

Volume 4 Number 2 March 2003 PDF

1 March 2003. Related: PDFs.

6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow, UK

1 February 2003. Related: Conference reports.

Volume 4 Number 1 January/February 2003

1 February 2003. Related: Editorial.

Combination of three generic drugs in one pill meets bioequivalence criteria when compared with the branded drugs: Triomune vs d4T/3TC/NVP

1 February 2003. Related: Conference reports, Antiretrovirals, Treatment access.

An overview of the conference

1 February 2003. Related: Conference reports, Antiretrovirals, Lipodystrophy and metabolic complications.

Pharmacokinetic evaluation of tenofovir and enteric-coated ddI

1 February 2003. Related: Conference reports, Antiretrovirals, PK and drug interactions.

The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates

1 February 2003. Related: Conference reports, Antiretrovirals, Treatment strategies, Hepatitis coinfection, Drug resistance.

Promising data regarding DermaVir for therapeutic vaccine

1 February 2003. Related: Conference reports, Basic science and immunology.

Enfuvirtide (T-20): predicting success and modelling survival benefits

1 February 2003. Related: Conference reports, Antiretrovirals, Drug resistance.

Virologic failure among treatment-naive patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz

1 February 2003. Related: Conference reports, Antiretrovirals.

Comparison of the efficacy and safety of tenofovir vs. d4T when used in combination with 3TC and efavirenz in ARV-naive patients

1 February 2003. Related: Conference reports, Antiretrovirals, Side effects, Lipodystrophy and metabolic complications.

Safety profile of tenofovir in treatment-experienced patients

1 February 2003. Related: Conference reports, Antiretrovirals, Side effects.

Lancet special report examines direction new WHO director general should take on several HIV/AIDS-related issues

1 February 2003. Related: Treatment access.

Roche and Trimeris able to make enough enfuvirtide (T-20) for only 12,000 people this year, 32,000 next year, citing difficulties in the manufacturing process

1 February 2003. Related: Antiretrovirals.

Vertex Pharmaceuticals announces submission of NDA/MAA filings in US and Europe for amprenavir pro-drug (GW433908)

1 February 2003. Related: Antiretrovirals.

BMS submits new drug application for investigational protease inhibitior atazanavir

1 February 2003. Related: Antiretrovirals.

Europe and America approve once-a-day stavudine (d4T, Zerit)

1 February 2003. Related: Antiretrovirals.

Tenofovir as HIV prevention: study to reduce HIV transmission in sexually active adults

1 February 2003. Related: Antiretrovirals.

Boehringer chooses dose for phase III studies of tipranavir/ritonavir PI combination

1 February 2003. Related: Antiretrovirals.

Adipose tissue alterations develop early in antiretroviral therapy

1 February 2003. Related: Lipodystrophy and metabolic complications.

Breadth of memory CTL response against HIV associated with immune control

1 February 2003. Related: Basic science and immunology.

Dendritic-cell vaccine elicits strong anti-SIV response in monkeys

1 February 2003. Related: Basic science and immunology.

HIV infection causes fibrosis in lymphatic tissue, diminishing CD4+ pool

1 February 2003. Related: Basic science and immunology.

Chronic immune activation: a lethal factor in HIV infection?

1 February 2003. Related: Basic science and immunology.

Website run by a nun in a caravan is nominated for awards

1 February 2003. Related: Other news.